With Americans increasingly concerned about drug prices and the Trump administration’s drug-pricing blueprintsupporting free-market pathways, the overriding question is: How do we inject more competition into the system by which drugs are purchased and dispensed?  Food and Drug Administration Commissioner Scott Gottlieb has already moved to accelerate generic drug approvals, and now he wants to repeat that success by galvanizing the market for biosimilars, where products could be priced between 20-30 percent lower than their innovator brand cousins.